University of Zurich at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
University of Zurich brings 3 presentations to ESGCT 2026 in Hamburg. Its contributions centre on in vivo base and prime editing to correct metabolic liver diseases, with a machine learning model that predicts base editor off-target activity. It also brings a high-capacity adenovirus for targeting the blood vessels that feed tumours.
| Organization | ESGCT 2026 Attendance |
|---|---|
University of Zurich Zurich, Switzerland | |
Swiss university whose groups use base and prime editing to correct metabolic liver diseases in vivo. | Talk Wed Oct 28 11:30am–12:30pm Correction of Metabolic Liver Diseases by In Vivo Base and Prime Editing Gene and epigenome editingRare and inherited disease Poster Wed Oct 28 1:30pm–3:30pm Engineering a novel high-capacity adenovirus-based system for ligand-independent targeting of tumor neovasculature and spatially controlled paracrine delivery of therapeutic biomolecules Poster Thu Oct 29 2:00pm–4:00pm ProBE-OFF: Highly accurate base editor off-target prediction using a mechanistic machine learning model Chair Thu Oct 29 4:00pm–6:00pm SESSION 9c: Immunotherapy and CAR T cells III Cell therapies and CAR-T Chair Fri Oct 30 11:00am–1:00pm SESSION 12b: Genome Editing III Gene and epigenome editing |
Instantly find 20 buyers from University of Zurich
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction